AZD-6918

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206220

CAS#: 905585-60-6

Description: AZD6918 is a novel potent and selective inhibitor of the Trk tyrosine kinases. AZD-6918 attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo. AZD6918 inhibited wild-type TrkB-induced cell migration and cell growth.


Chemical Structure

img
AZD-6918
CAS# 905585-60-6

Theoretical Analysis

MedKoo Cat#: 206220
Name: AZD-6918
CAS#: 905585-60-6
Chemical Formula: C20H20F2N6O
Exact Mass: 398.1667
Molecular Weight: 398.4178
Elemental Analysis: C, 60.29; H, 5.06; F, 9.54; N, 21.09; O, 4.02

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: AZD-6918; AZD6918; AZD 6918.

IUPAC/Chemical Name: (S)-5-Fluoro-2-[[1-(4-fluorophenyl)ethyl]amino]-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]nicotinonitrile

InChi Key: QRAQXWWNHQMCBH-LBPRGKRZSA-N

InChi Code: InChI=1S/C20H20F2N6O/c1-11(2)29-18-9-17(27-28-18)25-20-16(22)8-14(10-23)19(26-20)24-12(3)13-4-6-15(21)7-5-13/h4-9,11-12H,1-3H3,(H3,24,25,26,27,28)/t12-/m0/s1

SMILES Code: N#CC1=C(N[C@H](C2=CC=C(F)C=C2)C)N=C(NC3=NNC(OC(C)C)=C3)C(F)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 398.4178 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Li Z, Zhang Y, Tong Y, Tong J, Thiele CJ. Trk inhibitor attenuates the
BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and
in vivo. Cancer Biol Ther. 2015;16(3):477-83. doi: 10.1080/15384047.2015.1016659.
PubMed PMID: 25700942; PubMed Central PMCID: PMC4623105.

2: Harada T, Yatabe Y, Takeshita M, Koga T, Yano T, Wang Y, Giaccone G. Role and
relevance of TrkB mutations and expression in non-small cell lung cancer. Clin
Cancer Res. 2011 May 1;17(9):2638-45. doi: 10.1158/1078-0432.CCR-10-3034. PubMed
PMID: 21242122; PubMed Central PMCID: PMC3086954.



Additional Information

Phase I clinical trial for AZD-6918 was started in 2009. However, AZD6918 was discontinued from development due to an unacceptable pharmacokinetic profile. Drug was discontinued in 2009.